ChemoCentryx, Inc. has submitted a NDA to the FDA for avacopan for the treatment of patients with ANCA-associated vasculitis.
ChemoCentryx, Inc. confirmed that the Company has submitted a New Drug Application (NDA) to the FDA for avacopan for the treatment of patients with ANCA-associated vasculitis. The Company’s… read more.